top of page

In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients

  • Nov 16, 2024
  • 1 min read

CEO Rohan Palekar describes this result that was presented at the meeting, as well as other biomarker findings. Plus, he highlights three phase 3 trials the company currently has ongoing, including one that will read out next year.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page